Show Notes
(
00:32)
Would you mind telling our listeners a little about yourself and your background?
(
01:16)
This evaluation is about CIDP — chronic inflammatory demyelinating polyneuropathy, correct?
(
02:16)
Can you give us an overview of what the CIDP evaluation will consist of?
(
04:38)
Our standalone test for neurofascin-155 won't change, but will be rolled into this new test along with contactin-1, correct?
(
06:41)
This is a very rare disease with subtle clues, so does it make logical sense to pair these two antibodies?
(
08:07)
Why did we choose a cell-binding assay over a western blot or other methodology? Is there a reason why contactin-1 is better on CBA methodology?
(
09:40)
Can you elaborate on what this phenotype-specific approach means for neurologists, and how it makes their ordering easier?
(
11:14)
Even though it's hard to determine exactly what test to order for these patients, testing too broadly can just add to the confusion. Is a narrowed evaluation that answers specific questions more helpful?
(
14:42)
Can you give us any clues as to when a physician shouldn't order this test because it's unlikely to be positive?
(
15:51)
How does this test drive patient care? A lot of these patients are therapy refractory. What would be the second- or third-level treatment? Is there any oncological association with antibody positivity?
(
18:44)
Are there any alternative options for diagnostic answers for this challenging patient population?
(
20:44)
What is the key takeaway? What excites you most about this new test launch?